Molyneux Medico-Legal and Consulting Limited - Period Ending 2023-03-31

Molyneux Medico-Legal and Consulting Limited - Period Ending 2023-03-31


Molyneux Medico-Legal and Consulting Limited 8931894 false 2022-04-01 2023-03-31 2023-03-31 The principal activity of the company is the provision of neuroradiology consultancy services. Digita Accounts Production Advanced 6.30.9574.0 true 8931894 2022-04-01 2023-03-31 8931894 2023-03-31 8931894 bus:OrdinaryShareClass1 2023-03-31 8931894 bus:OrdinaryShareClass2 2023-03-31 8931894 bus:OrdinaryShareClass3 2023-03-31 8931894 bus:OrdinaryShareClass4 2023-03-31 8931894 bus:OrdinaryShareClass5 2023-03-31 8931894 core:RetainedEarningsAccumulatedLosses 2023-03-31 8931894 core:ShareCapital 2023-03-31 8931894 core:CurrentFinancialInstruments 2023-03-31 8931894 core:CurrentFinancialInstruments core:WithinOneYear 2023-03-31 8931894 core:Non-currentFinancialInstruments 2023-03-31 8931894 core:Non-currentFinancialInstruments core:AfterOneYear 2023-03-31 8931894 core:Goodwill 2023-03-31 8931894 core:FurnitureFittingsToolsEquipment 2023-03-31 8931894 core:MotorVehicles 2023-03-31 8931894 core:KeyManagementPersonnelCloseFamilyMembersEntitiesUnderKeyManagementPersonnelsControl 2023-03-31 8931894 bus:SmallEntities 2022-04-01 2023-03-31 8931894 bus:AuditExemptWithAccountantsReport 2022-04-01 2023-03-31 8931894 bus:FullAccounts 2022-04-01 2023-03-31 8931894 bus:SmallCompaniesRegimeForAccounts 2022-04-01 2023-03-31 8931894 bus:RegisteredOffice 2022-04-01 2023-03-31 8931894 bus:Director1 2022-04-01 2023-03-31 8931894 bus:Director2 2022-04-01 2023-03-31 8931894 bus:Director3 2022-04-01 2023-03-31 8931894 bus:Director4 2022-04-01 2023-03-31 8931894 bus:Director5 2022-04-01 2023-03-31 8931894 bus:OrdinaryShareClass1 2022-04-01 2023-03-31 8931894 bus:OrdinaryShareClass2 2022-04-01 2023-03-31 8931894 bus:OrdinaryShareClass3 2022-04-01 2023-03-31 8931894 bus:OrdinaryShareClass4 2022-04-01 2023-03-31 8931894 bus:OrdinaryShareClass5 2022-04-01 2023-03-31 8931894 bus:PrivateLimitedCompanyLtd 2022-04-01 2023-03-31 8931894 core:Goodwill 2022-04-01 2023-03-31 8931894 core:FurnitureFittings 2022-04-01 2023-03-31 8931894 core:FurnitureFittingsToolsEquipment 2022-04-01 2023-03-31 8931894 core:MotorVehicles 2022-04-01 2023-03-31 8931894 core:OfficeEquipment 2022-04-01 2023-03-31 8931894 core:KeyManagementPersonnel 2022-04-01 2023-03-31 8931894 core:KeyManagementPersonnelCloseFamilyMembersEntitiesUnderKeyManagementPersonnelsControl 2022-04-01 2023-03-31 8931894 countries:EnglandWales 2022-04-01 2023-03-31 8931894 2022-03-31 8931894 core:Goodwill 2022-03-31 8931894 core:FurnitureFittingsToolsEquipment 2022-03-31 8931894 core:MotorVehicles 2022-03-31 8931894 core:KeyManagementPersonnelCloseFamilyMembersEntitiesUnderKeyManagementPersonnelsControl 2022-03-31 8931894 2021-04-01 2022-03-31 8931894 2022-03-31 8931894 bus:OrdinaryShareClass1 2022-03-31 8931894 bus:OrdinaryShareClass2 2022-03-31 8931894 bus:OrdinaryShareClass3 2022-03-31 8931894 bus:OrdinaryShareClass4 2022-03-31 8931894 bus:OrdinaryShareClass5 2022-03-31 8931894 core:RetainedEarningsAccumulatedLosses 2022-03-31 8931894 core:ShareCapital 2022-03-31 8931894 core:CurrentFinancialInstruments 2022-03-31 8931894 core:CurrentFinancialInstruments core:WithinOneYear 2022-03-31 8931894 core:Non-currentFinancialInstruments 2022-03-31 8931894 core:Non-currentFinancialInstruments core:AfterOneYear 2022-03-31 8931894 core:Goodwill 2022-03-31 8931894 core:FurnitureFittingsToolsEquipment 2022-03-31 8931894 core:MotorVehicles 2022-03-31 8931894 core:KeyManagementPersonnelCloseFamilyMembersEntitiesUnderKeyManagementPersonnelsControl 2022-03-31 8931894 bus:OrdinaryShareClass1 2021-04-01 2022-03-31 8931894 bus:OrdinaryShareClass2 2021-04-01 2022-03-31 8931894 bus:OrdinaryShareClass3 2021-04-01 2022-03-31 8931894 bus:OrdinaryShareClass4 2021-04-01 2022-03-31 8931894 bus:OrdinaryShareClass5 2021-04-01 2022-03-31 8931894 core:KeyManagementPersonnelCloseFamilyMembersEntitiesUnderKeyManagementPersonnelsControl 2021-04-01 2022-03-31 8931894 2021-03-31 8931894 core:KeyManagementPersonnelCloseFamilyMembersEntitiesUnderKeyManagementPersonnelsControl 2021-03-31 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 8931894

Molyneux Medico-Legal and Consulting Limited

Annual Report and Unaudited Financial Statements

for the Year Ended 31 March 2023

 

Molyneux Medico-Legal and Consulting Limited

Company Information

Directors

Dr A J Molyneux

Dr A J Molyneux

Miss C A Morris

Mrs J Molyneux

Mr D C A Molyneux

Registered office

Innovations House
19 Staple Gardens
Winchester
Hampshire
SO23 8SR

Accountants

Tax Innovations Limited
Innovations House
19 Staple Gardens
Winchester
Hampshire
SO23 8SR

 

Molyneux Medico-Legal and Consulting Limited

(Registration number: 8931894)
Balance Sheet as at 31 March 2023

Note

2023
£

2022
£

Fixed assets

 

Intangible assets

4

39,594

46,193

Tangible assets

5

35,709

28,034

 

75,303

74,227

Current assets

 

Debtors

6

66,006

31,219

Cash at bank and in hand

 

32,417

33,856

 

98,423

65,075

Creditors: Amounts falling due within one year

7

(27,411)

(17,327)

Net current assets

 

71,012

47,748

Total assets less current liabilities

 

146,315

121,975

Creditors: Amounts falling due after more than one year

7

-

(7,997)

Net assets

 

146,315

113,978

Capital and reserves

 

Called up share capital

8

80

80

Retained earnings

146,235

113,898

Shareholders' funds

 

146,315

113,978

 

Molyneux Medico-Legal and Consulting Limited

(Registration number: 8931894)
Balance Sheet as at 31 March 2023

For the financial year ending 31 March 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the Board on 20 December 2023 and signed on its behalf by:
 

.........................................
Dr A J Molyneux
Director

 

Molyneux Medico-Legal and Consulting Limited

Notes to the Financial Statements for the Year Ended 31 March 2023

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
Innovations House
19 Staple Gardens
Winchester
Hampshire
SO23 8SR
England

The principal place of business is:
3 Walnut Close
Wootton
Woodstock
OX20 1DA

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
- the amount of revenue can be reliably measured;
- it is probable that future economic benefits will flow to the entity; and
- specific criteria have been met for each of the company's activities.

Foreign currency transactions and balances

Transactions in foreign currencies are initially recorded at the functional currency rate prevailing at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated into the respective functional currency of the entity at the rates prevailing on the reporting period date. Non-monetary items carried at fair value that are denominated in foreign currencies are retranslated at the rate on the date when the fair value is re-measured.

Non-monetary items measured in terms of historical cost in a foreign currency are not retranslated.

 

Molyneux Medico-Legal and Consulting Limited

Notes to the Financial Statements for the Year Ended 31 March 2023

Tax

The tax expense for the period comprises current tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Fixture and fittings

25% straight line

Office equipment

33% straight line

Motor vehicle

20% reducing balance

Goodwill

Goodwill arising on the acquisition of an entity represents the excess of the cost of acquisition over the company’s interest in the net fair value of the identifiable assets, liabilities and contingent liabilities of the entity recognised at the date of acquisition. Goodwill is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is held in the currency of the acquired entity and revalued to the closing rate at each reporting period date. Goodwill is amortised over its useful life, which shall not exceed ten years if a reliable estimate of the useful life cannot be made.

Amortisation

Amortisation is provided on intangible assets so as to write off the cost, less any estimated residual value, over their useful life as follows:

Asset class

Amortisation method and rate

Goodwill

Straight line basis over 15 years

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

 

Molyneux Medico-Legal and Consulting Limited

Notes to the Financial Statements for the Year Ended 31 March 2023

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Borrowings

Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the profit and loss account over the period of the relevant borrowing.

Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges.

Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

Leases

Leases in which substantially all the risks and rewards of ownership are retained by the lessor are classified as operating leases. Payments made under operating leases are charged to profit or loss on a straight-line basis over the period of the lease.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Dividends

Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

3

Staff numbers

The average number of persons employed by the company (including directors) during the year, was 5 (2022 - 5).

 

Molyneux Medico-Legal and Consulting Limited

Notes to the Financial Statements for the Year Ended 31 March 2023

4

Intangible assets

Goodwill
 £

Total
£

Cost or valuation

At 1 April 2022

98,985

98,985

At 31 March 2023

98,985

98,985

Amortisation

At 1 April 2022

52,792

52,792

Amortisation charge

6,599

6,599

At 31 March 2023

59,391

59,391

Carrying amount

At 31 March 2023

39,594

39,594

At 31 March 2022

46,193

46,193

5

Tangible assets

Furniture, fittings and equipment
 £

Motor vehicles
 £

Total
£

Cost or valuation

At 1 April 2022

14,315

38,697

53,012

Additions

3,536

34,658

38,194

Disposals

-

(38,697)

(38,697)

At 31 March 2023

17,851

34,658

52,509

Depreciation

At 1 April 2022

12,595

12,383

24,978

Charge for the year

1,317

5,958

7,275

Eliminated on disposal

-

(15,453)

(15,453)

At 31 March 2023

13,912

2,888

16,800

Carrying amount

At 31 March 2023

3,939

31,770

35,709

At 31 March 2022

1,720

26,314

28,034

 

Molyneux Medico-Legal and Consulting Limited

Notes to the Financial Statements for the Year Ended 31 March 2023

6

Debtors

Current

2023
£

2022
£

Trade debtors

34,100

27,980

Other debtors

31,906

3,239

 

66,006

31,219

7

Creditors

Creditors: amounts falling due within one year

2023
£

2022
£

Due within one year

Taxation and social security

24,511

14,427

Accruals and deferred income

2,900

2,900

27,411

17,327

Creditors: amounts falling due after more than one year

Note

2023
£

2022
£

Due after one year

 

Loans and borrowings

9

-

7,997

8

Share capital

Allotted, called up and fully paid shares

 

2023

2022

 

No.

£

No.

£

Ordinary A Shares of £1 each

34

34

34

34

Ordinary B Shares of £1 each

34

34

34

34

Ordinary C Shares of £1 each

4

4

4

4

Ordinary D Shares of £1 each

4

4

4

4

Ordinary E Shares of £1 each

4

4

4

4

 

80

80

80

80

 

Molyneux Medico-Legal and Consulting Limited

Notes to the Financial Statements for the Year Ended 31 March 2023

9

Loans and borrowings

2023
£

2022
£

Non-current loans and borrowings

Bank borrowings

-

7,997

10

Dividends

Interim dividends paid

   

2023
£

 

2022
£

Interim dividend of £58.82 per each Ordinary A Shares

 

2,000

 

2,000

Interim dividend of £Nil (2022 - £58.82) per each Ordinary B Shares

 

-

 

2,000

Interim dividend of £500.00 per each Ordinary C Shares

 

2,000

 

2,000

Interim dividend of £Nil (2022 - £500.00) per each Ordinary D Shares

 

-

 

2,000

Interim dividend of £500.00 per each Ordinary E Shares

 

2,000

 

2,000

   

6,000

 

10,000

11

Related party transactions

Directors' remuneration

The directors' remuneration for the year was as follows:

2023
£

2022
£

Remuneration

6,050

2,000

Loans to related parties

2023

Key management
£

Total
£

At start of period

100

100

Advanced

23,552

23,552

At end of period

23,652

23,652

 

Molyneux Medico-Legal and Consulting Limited

Notes to the Financial Statements for the Year Ended 31 March 2023

2022

Key management
£

Total
£

At start of period

730

730

Advanced

100

100

Repaid

(730)

(730)

At end of period

100

100

Terms of loans to related parties

Loan to directors are on a non fixed repayment basis with 0% interest charged.